Error loading player: No playable sources found

ATMPs/C&GT - Data Science and R&D

Date
June 29, 2022

ATMPs and/or C&GT when applied to the world of Research and Development and Data Science require specific approaches compared to its manufacturing counterpart. Due to the small processing volumes, a Scale Out approach is implemented over a Scale Up approach. Unlike Mab therapy that begins from a Working Cell Bank, ATMPs begin with the patient itself and the variability of the starting material is what characterizes the uniqueness behind personalized medicine. The R&D efforts for ATMPs are focused on a five-dimensional framework where the “five R’s” incorporates notions regarding the right target, the right tissue, the right safety, the right patients, and the right commercial potential. This session invites attendees to explore novel and collaborative methods to achieve a consistent robust process in developing a sustainable, scalable manufacturing platform. Improvements in smart manufacturing of ATMPs/C> supported by AI tools, digitalization and data science are key drivers to scientific, technical and operational progress. Coupled with non-invasive sensors for process monitoring along with dynamic contamination control strategies, the pathway from bench scale to market through smart manufacturing of ATMPs becomes a more tangible reality.

Speakers

Speaker Image for Laura-Ann Chin
Laura-Ann S. Chin, BSc, MSc, PE
Director, Life Sciences, Barry-Wehmiller Design Group
Speaker Image for Christian Lavarreda
Director of Business Development, Syntegon
Speaker Image for Kimberley Buytaert-Hoefen
Executive Director and Global Head of Regulatory Affairs, QPS LLC
Speaker Image for Kevin Baughman
Director of Consulting Services, Aizon
Speaker Image for Christoph Herwig
Senior Scientific Advisor, Körber Pharma Austria
Speaker Image for Antonio Moreira
Vice Provost, Academic Affairs, University of Maryland
Speaker Image for Dena Flamm
Business Development Manager, OPTIMA Pharma
Speaker Image for Lars Waldmann
Staff Engineer, Viral Vector Services, Thermo Fisher Scientific

Related Products

Thumbnail for Sustainability in Biopharma Critical Utilities
Sustainability in Biopharma Critical Utilities
Five years into the revision to monograph 0169 of the European Pharmacopoeia allowing methods other than distillation for the generation of WFI, and among the current turmoil in the energy markets, how are the economic and sustainability considerations evolving in biopharmaceutical critical utility…
Thumbnail for Challenges and Opportunities in Plant to Patient Supply
Challenges and Opportunities in Plant to Patient Supply
Innovation in challenging times has reshaped the global pharmaceutical manufacturing supply infrastructure…
Thumbnail for Tomorrow's Modular Frameworks for Advanced Manufacturing
Tomorrow's Modular Frameworks for Advanced Manufacturing
Integral to time to market in the (bio)pharmaceutical industry, the need for enhanced functionality and compliance in manufacturing operations continues to grow rapidly…